When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 19 Mar 2025
Last updated: 05 Dec 2024

Summary

Definition

History and exam

Other diagnostic factors

  • cervical discharge
  • friable cervix
  • abnormal vaginal bleeding
  • penile discharge
  • vaginal discharge
  • dysuria
  • pelvic pain
  • fever/chills
  • nausea/vomiting
  • scrotal pain
  • myalgias
  • abdominal pain
  • mucopurulent rectal discharge or tenesmus
  • joint pain and swelling
  • eye irritation
  • rashes
  • inflammation

Risk factors

  • age under 25 years, sexually active
  • new sex partner or multiple sex partners
  • sexual activity with infected partner
  • condoms not used
  • history of prior STI
  • ethnicity
  • urban residence and low socioeconomic status

Diagnostic tests

1st tests to order

  • nucleic acid amplification test (NAAT)

Tests to consider

  • direct immunofluorescence
  • enzyme immunoassay
  • nucleic acid hybridization tests
  • cell culture

Emerging tests

  • rapid and point-of-care tests

Treatment algorithm

Contributors

Authors

Matthew M. Hamill, MBChB, PhD, FRCP

Assistant Professor of Medicine

Johns Hopkins University School of Medicine

Baltimore

MD

Disclosures

MMH receives royalties for contributing to UpToDate on Lymphogranuloma venereum and for Clinical Care Options. He has an honorarium from Roche Diagnostics for panel STI & HIV 2021 World Congress (virtual) and was a member of the 2021 Roche group on future of POCT for STI. He has also received consulting fees from GSK for the HSV vaccine.

Acknowledgements

Dr Matthew M. Hamill would like to gratefully acknowledge Dr Anne Rompalo and Dr Christopher K. Fairley, the previous contributors to this topic.

Disclosures

AR and CKF declare that they have no competing interests.

Peer reviewers

Kenneth Lin, MD

Assistant Editor

American Family Physician

Clinical Assistant Professor

GUSOM Medical Officer

US Preventive Services Task Force

Disclosures

KL declares that he has no competing interests.

Lars Jørgen Østergaard, MD, PhD, DMSc

Professor/Head

Department of Infectious Diseases

Aarhus University Hospital

Skejby Sygehus

Aarhus

Denmark

Disclosures

LJO has been funded by Pfizer to write a leaflet on Chlamydia infections.

Use of this content is subject to our disclaimer